| Literature DB >> 29671588 |
Richard W Fitch1, Barry B Snider2, Quan Zhou2, Bruce M Foxman2, Anshul A Pandya3, Jerrel L Yakel3, Thao T Olson4, Nour Al-Muhtasib4, Yingxian Xiao4, Kevin D Welch5, Kip E Panter5.
Abstract
Phantasmidine, a rigid congener of the well-known nicotinic acetylcholine receptor agonist epibatidine, is found in the same species of poison frog ( Epipedobates anthonyi). Natural phantasmidine was found to be a 4:1 scalemic mixture, enriched in the (2a R,4a S,9a S) enantiomer by chiral-phase LC-MS comparison to the synthetic enantiomers whose absolute configurations were previously established by Mosher's amide analysis. The major enantiomer has the opposite S configuration at the benzylic carbon to natural epibatidine, whose benzylic carbon is R. Pharmacological characterization of the synthetic racemate and separated enantiomers established that phantasmidine is ∼10-fold less potent than epibatidine, but ∼100-fold more potent than nicotine in most receptors tested. Unlike epibatidine, phantasmidine is sharply enantioselective in its activity and the major natural enantiomer whose benzylic carbon has the 4a S configuration is more active. The stereoselective pharmacology of phantasmidine is ascribed to its rigid and asymmetric shape as compared to the nearly symmetric conformations previously suggested for epibatidine enantiomers. While phantasmidine itself is too toxic for direct therapeutic use, we believe it is a useful platform for the development of potent and selective nicotinic agonists, which may have value as pharmacological tools.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29671588 PMCID: PMC7142328 DOI: 10.1021/acs.jnatprod.8b00062
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050